Swiss National Bank’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.86M | Buy |
566,200
+82,900
| +17% | +$419K | ﹤0.01% | 1595 |
|
|
2025
Q1 | $2.56M | Sell |
483,300
-3,400
| -0.7% | -$18K | ﹤0.01% | 1617 |
|
|
2024
Q4 | $3.29M | Buy |
486,700
+129,600
| +36% | +$876K | ﹤0.01% | 1556 |
|
|
2024
Q3 | $2.35M | Buy |
357,100
+1,900
| +0.5% | +$12.5K | ﹤0.01% | 1776 |
|
|
2024
Q2 | $2.66M | Buy |
355,200
+46,700
| +15% | +$350K | ﹤0.01% | 1668 |
|
|
2024
Q1 | $3.08M | Buy |
308,500
+27,100
| +10% | +$270K | ﹤0.01% | 1598 |
|
|
2023
Q4 | $2.77M | Sell |
281,400
-2,700
| -1% | -$26.6K | ﹤0.01% | 1657 |
|
|
2023
Q3 | $2.17M | Buy |
284,100
+4,600
| +2% | +$35.2K | ﹤0.01% | 1790 |
|
|
2023
Q2 | $2.09M | Buy |
279,500
+161,900
| +138% | +$1.21M | ﹤0.01% | 1859 |
|
|
2023
Q1 | $784K | Sell |
117,600
-2,000
| -2% | -$13.3K | ﹤0.01% | 2377 |
|
|
2022
Q4 | $922K | Buy |
119,600
+3,100
| +3% | +$23.9K | ﹤0.01% | 2385 |
|
|
2022
Q3 | $1.24M | Buy |
116,500
+3,700
| +3% | +$39.4K | ﹤0.01% | 2211 |
|
|
2022
Q2 | $918K | Buy |
112,800
+18,500
| +20% | +$151K | ﹤0.01% | 2415 |
|
|
2022
Q1 | $675K | Buy |
94,300
+6,700
| +8% | +$48K | ﹤0.01% | 2533 |
|
|
2021
Q4 | $1.5M | Buy |
+87,600
| New | +$1.5M | ﹤0.01% | 2228 |
|